High-Resolution Anoscopy — CPB 0808 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0808 governing high-resolution anoscopy coverage, effective November 22, 2025. Billing teams should audit claims for CPT 46601 and 46607 now — coverage is narrow, and the denial exposure is real.

Aetna's updated high-resolution anoscopy coverage policy under CPB 0808 in the Aetna system draws a hard line between covered diagnostic and ablative uses and procedures the payer considers experimental. CPT 46601 (diagnostic HRA) and CPT 46607 (HRA with biopsy and chemical treatment) are covered — but only for specific clinical indications. Bill outside those indications and you're looking at a claim denial with no clear path to appeal.

Aetna High-Resolution Anoscopy Coverage Criteria and Medical Necessity Requirements 2025

The Aetna high-resolution anoscopy coverage policy is specific about what clears the medical necessity bar. There are exactly two covered indications. Know both.

Covered indication one: Diagnosis of a suspicious anal lesion in patients with abnormal anal physical findings. This includes anogenital warts (A63.0), hypo-pigmented or hyper-pigmented plaques or lesions, lesions that bleed, lesions of uncertain etiology, or cytological abnormalities with clinical suspicion of dysplasia. The clinical picture has to be there before you bill CPT 46601.

Covered indication two: HRA guidance for biopsy and ablation of high-grade anal intraepithelial neoplasia (HGAIN). This is the indication that supports billing CPT 46607 — the code that includes high-resolution magnification plus chemical treatment (e.g., acetic acid application). If your provider is performing ablation or biopsy under HRA guidance for confirmed HGAIN, you have a payable claim.

Medical necessity documentation needs to reflect one of these two scenarios clearly. A vague referral note or a general "anal lesion" won't hold up. The clinical record should tie directly to the ICD-10 codes Aetna lists — D01.3 (carcinoma in situ of anus and anal canal), C21.0 or C21.1 (malignant neoplasm of anal canal), C44.520 (squamous cell carcinoma of anal skin), or the K62.x series for other anal and rectal diseases, depending on the clinical picture.

CPB 0808 in the Aetna system does not explicitly list a prior authorization requirement for these procedures. That said, given the narrow covered indications and the payer's history with procedures in this category, verify prior auth requirements at the plan level before scheduling — especially for commercial and managed care products. Don't assume the CPB absence of a PA requirement means your specific plan product doesn't require one.

High-resolution anoscopy billing under this policy requires you to map the clinical finding to the right ICD-10 before the claim goes out. Diagnosis codes drive the coverage decision here as much as the CPT code does.

Aetna High-Resolution Anoscopy Exclusions and Non-Covered Indications

This is where the policy gets restrictive — and where most claim denials will come from.

Aetna classifies three uses of HRA as experimental, investigational, or unproven. "Experimental" in Aetna policy language means no reimbursement, full stop. These aren't gray areas.

Excluded use one: Estimation of treatment failure risk for anal canal carcinoma after chemoradiotherapy. If a provider is using HRA post-chemoradiation to assess residual disease or predict recurrence, that's not a covered service under this policy. Bill it and you'll get a denial.

Excluded use two: Screening of asymptomatic persons for anal dysplasia and anal cancer. This is the big one. High-risk populations — people with HIV, immunocompromised patients, those with a history of HPV-related disease — are increasingly offered anal cancer screening programs. Aetna does not cover HRA for asymptomatic screening, regardless of risk profile. The screening use case is explicitly excluded.

Excluded use three: Surveillance after treatment for anal squamous cell carcinoma. Post-treatment monitoring using HRA falls outside covered indications. Providers running surveillance protocols after squamous cell carcinoma treatment should not expect Aetna reimbursement for those procedures.

The real issue here is that these three excluded uses represent a significant portion of how HRA is actually practiced in high-volume colorectal and infectious disease settings. If your practice has active anal cancer screening or surveillance programs that bill Aetna, this coverage policy directly threatens that revenue stream. Talk to your compliance officer and billing consultant before November 22, 2025 if any of these scenarios describe your current billing patterns.

Coverage Indications at a Glance

Aetna High-Resolution Anoscopy Billing Guidelines and Action Items 2025

Act on these before November 22, 2025. If that date has already passed when you're reading this, do it today.

If your practice has significant exposure to the excluded indications — particularly HIV care or post-treatment oncology monitoring — loop in your compliance officer before the effective date. The risk here is pattern-level, not just individual claim denials.

CPT, HCPCS, and ICD-10 Codes for High-Resolution Anoscopy Under CPB 0808

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Both codes are covered only for the two listed medical necessity indications. Use 46601 for diagnostic HRA. Use 46607 when the procedure includes chemical treatment (e.g., acetic acid) along with biopsy or ablation guidance for HGAIN.

Key ICD-10-CM Diagnosis Codes

These are the codes Aetna lists in CPB 0808. Pairing the right ICD-10 to the right CPT is how you avoid a claim denial on the front end.

The full policy lists 115 ICD-10-CM codes across the K62.x range and related diagnosis categories. See the full CPB 0808 policy at app.payerpolicy.org/p/aetna/0808 for the complete code set.